# OnCo record nct04023526 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04023526/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04023526", "NCT04023526" ;
  schema:name "A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy"@en ;
  schema:alternateName "CULMINATE"@en ;
  schema:description "A phase 2 trial of Azacitidine and Cusatuzumab in acute myeloid leukaemia, run by OncoVerity, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04023526/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04023526> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2019-07-29" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/cusatuzumab/> ;
  onco:companies <https://onco.cc/companies/oncoverity/>, <https://onco.cc/companies/argenx/>, <https://onco.cc/companies/johnson-johnson/> .